DeepMed Research

VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

Phase 1

Recruiting

Conditions: HIV Infections

Interventions: Drug: Cabotegravir long-acting
Drug: Lenacapavir long-acting

First Posted Date: 2025-05-14

Last Posted Date: 2025-05-14

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 60

Registration Number: NCT06970223

Locations: 🇺🇸
GSK Investigational Site, Long Beach, California, United States

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)

Phase 2

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: CAB LA
Drug: New formulation of CAB LA

First Posted Date: 2025-03-25

Last Posted Date: 2025-04-02

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 191

Registration Number: NCT06741397

Locations: 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

Phase 1

Recruiting

Conditions: HIV Infections

Interventions: Drug: CAB LA
Drug: CAB ULA

First Posted Date: 2025-01-22

Last Posted Date: 2025-02-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 60

Registration Number: NCT06786520

Locations: 🇺🇸
GSK Investigational Site, Oak Brook, Illinois, United States

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

Phase 1

Recruiting

Conditions: HIV Infections

Interventions: Drug: VH4011499 Injection
Drug: Placebo for VH4011499 Injection

First Posted Date: 2024-12-09

Last Posted Date: 2025-05-15

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 168

Registration Number: NCT06724640

Locations: 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Phase 3

Recruiting

Conditions: HIV Infections

Interventions: Drug: CAB LA + RPV LA
Drug: Oral ART

First Posted Date: 2024-11-19

Last Posted Date: 2025-02-19

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 332

Registration Number: NCT06694805

Locations: 🇪🇸
GSK Investigational Site, Zaragoza, Spain

A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

Phase 1

Recruiting

Conditions: HIV Infections

Interventions: Biological: VH4527079

First Posted Date: 2024-10-22

Last Posted Date: 2025-04-23

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 86

Registration Number: NCT06652958

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Phase 1

Withdrawn

Conditions: HIV Infections

First Posted Date: 2024-08-01

Last Posted Date: 2025-04-22

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 91

Registration Number: NCT06533280

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Study to Investigate the Effect of Food on the Bioavailability of a Capsid Inhibitor (CAI) in Male and Female Healthy Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: VH4011499 Dose A
Drug: VH4011499 Dose B

First Posted Date: 2024-04-16

Last Posted Date: 2025-02-18

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 60

Registration Number: NCT06368986

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

First Time in Human Study of Long Acting VH4524184 Formulations

Phase 1

Recruiting

Conditions: HIV Infections

Interventions: Drug: Oral VH4524184
Drug: VH4524184 Formulation A SC
Drug: VH4524184 Formulation A IM
Drug: VH4524184 Formulation B IM
Drug: Placebo Formulation B IM
Drug: Placebo Formulation A SC
Drug: VH4524184 Formulation B SC
Drug: VH4524184 Formulation C SC
Drug: Placebo Formulation A IM
Drug: rHuPH20
Drug: Placebo Formulation B SC
Drug: Placebo Formulation C SC

First Posted Date: 2024-03-15

Last Posted Date: 2025-02-24

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 72

Registration Number: NCT06310551

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

A Study to Investigate the Potential Drug-Drug Interaction Between VH4524184 and Oral Contraceptive (Loestrin) in Healthy Adult Female Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: VH4524184
Drug: Loestrin

First Posted Date: 2024-03-15

Last Posted Date: 2024-12-10

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 26

Registration Number: NCT06310616

Locations: 🇺🇸
GSK Investigational Site, San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy